Richard T Silver1, Ariella C Barel1, Elena Lascu1, Ellen K Ritchie1, Gail J Roboz1, Paul J Christos2, Attilio Orazi3, Duane C Hassane4, Wayne Tam3, Nicholas C P Cross5. 1. Richard T Silver, MD Myeloproliferative Neoplasms Center, Division of Hematology-Medical Oncology, Weill Cornell Medicine, New York, New York. 2. Division of Biostatistics and Epidemiology, Department of Healthcare Policy and Research, Weill Cornell Medicine, New York, New York. 3. Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, New York. 4. Institute for Computational Biomedicine, Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, New York. 5. Faculty of Medicine, University of Southampton, Southampton, United Kingdom.
Abstract
BACKGROUND: Although recombinant interferon-α (rIFNα) effectively treats patients with early myelofibrosis, the effect of driver and high molecular risk (HMR) mutations has not been considered. In this phase 2 study, for the first time, the authors correlate response to rIFNα treatment with driver and HMR mutations. METHODS: Patients were diagnosed using World Health Organization or International Working Group for Myeloproliferative Neoplasms Research and Treatment criteria. Only patients who had low or intermediate-1 Dynamic International Prognostic Scoring System scores with ≥15% hematopoietic bone marrow foci were included. History, symptom assessment, physical examination, and blood and bone marrow studies were performed. Genomic DNA was extracted from frozen cells, and next-generation targeted sequencing of 45 genes was performed. Either rIFNα-2b (0.5 million units subcutaneously 3 times weekly) or pegylated rIFNα-2a (45 μg weekly) with escalation was initiated. All patients were followed at the authors' institution, and regular bone marrow biopsies were encouraged. International Working Group for Myeloproliferative Neoplasms Research and Treatment and European LeukemiaNet treatment response criteria were used. RESULTS: Of 30 patients (16 women and 14 men; median age, 58 years), 22 were classified as low risk, and 8 were classified as intermediate-1 risk. Two patients achieved complete remission, 9 achieved partial remission, 4 had clinical improvement, 7 had stable disease; 3 had progressive disease, 1 relapsed, and 4 died. There were 22 patients with JAK mutations, 6 with CALR mutations, and 2 with MPL mutations. Seventy-three percent of patients improved or remained stable with acceptable toxicity, including 37% who achieved complete or partial remission. There was no correlation between treatment response and baseline driver mutations or Dynamic International Prognostic Scoring System scores. Of 8 poor responders, 3 had ASXL1 or SRSF2 mutations. CONCLUSIONS: Early treatment with rIFNα in patients without HMR mutations may prevent the development of marked splenomegaly, anemia, and florid myelofibrosis. Molecular profiling at the time of diagnosis may predict prognosis and treatment response. Cancer 2017;123:2680-87.
BACKGROUND: Although recombinant interferon-α (rIFNα) effectively treats patients with early myelofibrosis, the effect of driver and high molecular risk (HMR) mutations has not been considered. In this phase 2 study, for the first time, the authors correlate response to rIFNα treatment with driver and HMR mutations. METHODS:Patients were diagnosed using World Health Organization or International Working Group for Myeloproliferative Neoplasms Research and Treatment criteria. Only patients who had low or intermediate-1 Dynamic International Prognostic Scoring System scores with ≥15% hematopoietic bone marrow foci were included. History, symptom assessment, physical examination, and blood and bone marrow studies were performed. Genomic DNA was extracted from frozen cells, and next-generation targeted sequencing of 45 genes was performed. Either rIFNα-2b (0.5 million units subcutaneously 3 times weekly) or pegylated rIFNα-2a (45 μg weekly) with escalation was initiated. All patients were followed at the authors' institution, and regular bone marrow biopsies were encouraged. International Working Group for Myeloproliferative Neoplasms Research and Treatment and European LeukemiaNet treatment response criteria were used. RESULTS: Of 30 patients (16 women and 14 men; median age, 58 years), 22 were classified as low risk, and 8 were classified as intermediate-1 risk. Two patients achieved complete remission, 9 achieved partial remission, 4 had clinical improvement, 7 had stable disease; 3 had progressive disease, 1 relapsed, and 4 died. There were 22 patients with JAK mutations, 6 with CALR mutations, and 2 with MPL mutations. Seventy-three percent of patients improved or remained stable with acceptable toxicity, including 37% who achieved complete or partial remission. There was no correlation between treatment response and baseline driver mutations or Dynamic International Prognostic Scoring System scores. Of 8 poor responders, 3 had ASXL1 or SRSF2 mutations. CONCLUSIONS: Early treatment with rIFNα in patients without HMR mutations may prevent the development of marked splenomegaly, anemia, and florid myelofibrosis. Molecular profiling at the time of diagnosis may predict prognosis and treatment response. Cancer 2017;123:2680-87.
Keywords:
bone marrow morphology; early primary and secondary myelofibrosis; high molecular risk; molecular profile; recombinant interferon-α (rIFNα) treatment; splenomegaly
Authors: Jan Philipp Bewersdorf; Smith Giri; Rong Wang; Nikolai Podoltsev; Robert T Williams; Raajit K Rampal; Martin S Tallman; Amer M Zeidan; Maximilian Stahl Journal: Clin Lymphoma Myeloma Leuk Date: 2020-05-28
Authors: Anders Lindholm Sørensen; Stine Ulrik Mikkelsen; Trine Alma Knudsen; Mads Emil Bjørn; Christen Lykkegaard Andersen; Ole Weis Bjerrum; Nana Brochmann; Dustin Andersen Patel; Lise Mette Rahbek Gjerdrum; Daniel El Fassi; Torben A Kruse; Thomas Stauffer Larsen; Hans Torben Mourits-Andersen; Claus Henrik Nielsen; Christina Ellervik; Niels Pallisgaard; Mads Thomassen; Lasse Kjær; Vibe Skov; Hans Carl Hasselbalch Journal: Haematologica Date: 2019-12-26 Impact factor: 9.941
Authors: Matthieu Mosca; Gurvan Hermange; Amandine Tisserand; Robert Noble; Christophe Marzac; Caroline Marty; Cécile Le Sueur; Hugo Campario; Gaëlle Vertenoeil; Mira El-Khoury; Cyril Catelain; Philippe Rameau; Cyril Gella; Julien Lenglet; Nicole Casadevall; Rémi Favier; Eric Solary; Bruno Cassinat; Jean-Jacques Kiladjian; Stefan N Constantinescu; Florence Pasquier; Michael E Hochberg; Hana Raslova; Jean-Luc Villeval; François Girodon; William Vainchenker; Paul-Henry Cournède; Isabelle Plo Journal: Blood Date: 2021-12-02 Impact factor: 22.113